Prophylactic human papillomavirus (HPV) vaccination programs constitute major public
health initiatives worldwide. We assessed the global effect of quadrivalent HPV (4vHPV) …

Introduction Human papillomavirus (HPV) infection, which poses significant disease burden,
is decreasing following implementation of vaccination programs. Synthesized evidence on …

Introduction Since 2007, many countries have implemented national human papillomavirus
(HPV) vaccination programs with the quadrivalent HPV (4HPV) vaccine that has been …

In 2014, the Food and Drug Administration approved a new human papillomavirus 9-valent
vaccine (9vHPV), targeting nine HPV types: HPV types 6, 11, 16, and 18, which are also …

Objective To provide family physicians with information on the efficacy, safety, public health
effects, and cost-effectiveness of the 9-valent human papillomavirus (HPV) vaccine. Quality …

The availability of prophylactic human papillomavirus (HPV) vaccines has provided powerful
tools for primary prevention of cervical cancer and other HPV-associated diseases. Since …

What is known and background: The introduction of vaccines has lead to a significant
reduction in morbidity and mortality from diseases such as measles, rubella and …

Since 2006, 115 countries and territories have introduced human papillomavirus (HPV)
vaccination programs. Several efforts have been undertaken to evaluate the impact of HPV …

Background The extent of cross-protection is a key element in the choice of human
papillomavirus (HPV) vaccine to use in vaccination programmes. We compared the cross …

Methods From October 2013 to February 2015, the ACIP HPV Vaccine Work Group
reviewed clinical trial data assessing the efficacy, immunogenicity, and safety of 9vHPV …